Keros Therapeutics Inc
KROS14.659USD
+0.339+2.37%
Horário de mercado （ET）Cotações atrasadas em 15 min
594.62MValor de mercado
141.17P/L TTM
Mais detalhes de Keros Therapeutics Inc Empresa
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its second product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its third product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
Informações da empresa
Código da empresaKROS
Nome da EmpresaKeros Therapeutics Inc
Data de listagemApr 08, 2020
CEODr. Jasbir Seehra, Ph.D.
Número de funcionários169
Tipo de títulosOrdinary Share
Fim do ano fiscalApr 08
Endereço1050 Waltham Street, Suite 302
CidadeLEXINGTON
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal02421
Telefone16173146297
Sitehttps://www.kerostx.com/
Código da empresaKROS
Data de listagemApr 08, 2020
CEODr. Jasbir Seehra, Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Jasbir Seehra, Ph.D.
Dr. Jasbir Seehra, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
302.22K
+19.52%
Mr. Julius Knowles
Mr. Julius Knowles
Independent Director
Independent Director
6.44K
+440.81%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Lead Independent Director
Lead Independent Director
5.45K
+2625.00%
Dr. Carl L. Gordon, Ph.D.
Dr. Carl L. Gordon, Ph.D.
Independent Director
Independent Director
5.25K
--
Mr. Nima Farzan
Mr. Nima Farzan
Independent Director
Independent Director
5.25K
--
Mr. Tomer Kariv, J.D.
Mr. Tomer Kariv, J.D.
Independent Director
Independent Director
5.25K
--
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
5.25K
--
Mr. Justin Frantz
Mr. Justin Frantz
Head of Investor Relations
Head of Investor Relations
--
--
Mr. Keith C. Regnante
Mr. Keith C. Regnante
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Mr. Christopher R. Rovaldi
Mr. Christopher R. Rovaldi
President, Chief Operating Officer
President, Chief Operating Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Jasbir Seehra, Ph.D.
Dr. Jasbir Seehra, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
302.22K
+19.52%
Mr. Julius Knowles
Mr. Julius Knowles
Independent Director
Independent Director
6.44K
+440.81%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Lead Independent Director
Lead Independent Director
5.45K
+2625.00%
Dr. Carl L. Gordon, Ph.D.
Dr. Carl L. Gordon, Ph.D.
Independent Director
Independent Director
5.25K
--
Mr. Nima Farzan
Mr. Nima Farzan
Independent Director
Independent Director
5.25K
--
Mr. Tomer Kariv, J.D.
Mr. Tomer Kariv, J.D.
Independent Director
Independent Director
5.25K
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: dom, 27 de jul
Atualizado em: dom, 27 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Adar1 Capital Management LLC
13.27%
Pontifax Venture Capital
11.79%
Madison Avenue Partners LP
6.44%
J.P. Morgan Securities LLC
6.32%
The Vanguard Group, Inc.
6.32%
Other
55.86%
Investidores
Investidores
Proporção
Adar1 Capital Management LLC
13.27%
Pontifax Venture Capital
11.79%
Madison Avenue Partners LP
6.44%
J.P. Morgan Securities LLC
6.32%
The Vanguard Group, Inc.
6.32%
Other
55.86%
Tipos de investidores
Investidores
Proporção
Hedge Fund
38.34%
Investment Advisor
21.28%
Investment Advisor/Hedge Fund
18.66%
Venture Capital
17.81%
Research Firm
10.83%
Private Equity
2.51%
Corporation
1.41%
Individual Investor
0.93%
Sovereign Wealth Fund
0.16%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
390
45.97M
113.19%
-7.37M
2025Q1
394
39.41M
98.81%
-8.43M
2024Q4
366
43.10M
106.25%
-873.01K
2024Q3
351
43.05M
114.83%
+404.61K
2024Q2
337
39.69M
109.09%
-4.15M
2024Q1
332
39.81M
110.03%
+1.08M
2023Q4
310
34.40M
109.87%
-229.62K
2023Q3
303
31.04M
104.70%
-2.97M
2023Q2
305
30.88M
104.58%
-2.59M
2023Q1
303
30.13M
102.36%
-2.18M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Adar1 Capital Management LLC
5.39M
13.27%
--
--
May 12, 2025
Pontifax Venture Capital
4.79M
11.79%
--
--
Apr 17, 2025
Madison Avenue Partners LP
2.61M
6.44%
+2.61M
--
May 14, 2025
J.P. Morgan Securities LLC
2.57M
6.32%
+2.38M
+1301.87%
Mar 31, 2025
The Vanguard Group, Inc.
2.57M
6.32%
+616.06K
+31.59%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.51M
6.18%
+40.82K
+1.65%
Mar 31, 2025
Logos Global Management LP
2.00M
4.92%
+2.00M
--
Mar 31, 2025
Nantahala Capital Management, LLC
1.51M
3.71%
+591.74K
+64.67%
Mar 31, 2025
State Street Global Advisors (US)
1.30M
3.21%
+99.16K
+8.24%
Mar 31, 2025
D. E. Shaw & Co., L.P.
1.26M
3.11%
+1.25M
+10339.95%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Janus Henderson Small Cap Growth Alpha ETF
1.06%
Virtus LifeSci Biotech Clinical Trials ETF
0.88%
Janus Henderson Small/Mid Cap Growth Alpha ETF
0.79%
Federated Hermes MDT Small Cap Core ETF
0.45%
ALPS Medical Breakthroughs ETF
0.37%
SPDR S&P Biotech ETF
0.18%
Direxion Daily S&P Biotech Bull 3X Shares
0.1%
Invesco Nasdaq Biotechnology ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.06%
iShares Biotechnology ETF
0.05%
Ver Mais
Janus Henderson Small Cap Growth Alpha ETF
Proporção1.06%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.88%
Janus Henderson Small/Mid Cap Growth Alpha ETF
Proporção0.79%
Federated Hermes MDT Small Cap Core ETF
Proporção0.45%
ALPS Medical Breakthroughs ETF
Proporção0.37%
SPDR S&P Biotech ETF
Proporção0.18%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.1%
Invesco Nasdaq Biotechnology ETF
Proporção0.06%
ProShares Ultra Nasdaq Biotechnology
Proporção0.06%
iShares Biotechnology ETF
Proporção0.05%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
